Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

most of our critical trial patients are

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crazyjogger925 Member Profile
 
Followed By 41
Posts 13,561
Boards Moderated 0
Alias Born 02/27/05
160x600 placeholder
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:32:42 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:32:41 PM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 11/30/2021 6:31:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:30:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:27:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/29/2021 6:20:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 5:22:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2021 4:05:01 PM
CytoDyn reports leronlimab data in NASH trial for first 15 patients Seeking Alpha - 11/24/2021 10:08:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2021 5:24:15 PM
SA Breaking News - PURA estimates $1M in 2022 revenue InvestorsHub NewsWire - 11/22/2021 9:38:18 AM
PURA BULLISH RESURGANCE InvestorsHub NewsWire - 11/19/2021 8:50:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/17/2021 6:02:41 AM
CytoDyn submits the first section of HIV BLA to FDA under rolling review Seeking Alpha - 11/16/2021 7:07:29 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2021 4:55:20 PM
CytoDyn submits leronlimab Breakthrough Therapy designation application to the FDA Seeking Alpha - 11/8/2021 7:50:43 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/5/2021 11:30:49 AM
CytoDyn posts preliminary results from mid-stage leronlimab NASH study Seeking Alpha - 11/3/2021 6:11:13 AM
iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST) InvestorsHub NewsWire - 10/29/2021 2:31:48 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/28/2021 2:06:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2021 1:58:46 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/27/2021 4:27:55 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/21/2021 4:10:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2021 4:07:39 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/20/2021 5:28:12 PM
crazyjogger925   Thursday, 11/25/21 04:19:50 PM
Re: justdafactss post# 194777
Post # of 196179 
most of our critical trial patients are critical and on ventilators too

READ: CytoDyn says Brazil approves pivotal Phase 3 clinical trial of leronlimab in critically ill coronavirus patients
CytoDyn said the new pivotal Phase 3 clinical trial will focus on hospitalized critically ill COVID-19 patients who require mechanical and invasive ventilation or Extracorporeal Membrane Oxygenation (ECMO). Its flagship Leronlimab drug will be administered via intravenous therapy (IV) in four doses or 700 milligrams (mg) per week. The trial is being conducted across 29 research centers with 316 patients.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences